Found 121 clinical trials
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)
- 344 views
- 08 Nov, 2020
- 1 location
![[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma](/media/imagery/259550.svg)
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
FES PET/CT imaging for invasive lobular cancer
- 0 views
- 14 Jul, 2022
- 1 location
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ
(the same enrolled clinicopathological features to cohort 1 of ECOG E5194 trial) demonstrated that the 7-year ipsilateral breast tumor recurrence (IBTR) ranged from 5.6% to 10.5% for low-risk ductal
- 18 views
- 14 Feb, 2022
- 1 location
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
therapy of high-risk early-stage triple-negative invasive ductal carcinoma. The Secondary purposes are to evaluate the safety of long-term use of Huaier granules as postoperative adjuvant treatment of
- 0 views
- 07 Jul, 2022
- 19 locations
Management of Low-risk (Grade I and II) DCIS (LORD)
A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns slow-growing low-risk DCIS (grade I and II). This implies that many women might be unnecessarily going through intensive treatment resulting in a decrease in quality of life and an increase in health care costs, …
- 464 views
- 04 Jun, 2022
- 51 locations
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial (COMET)
is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AM approach does not yield inferior cancer or quality of life outcomes compared to surgery.
- 1343 views
- 16 Oct, 2022
- 118 locations
Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with …
- 29 views
- 03 Jun, 2022
- 17 locations
Well-Being After Breast Cancer Surgery (WB ABCs)
breast surgery for lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive breast cancer, and to examine the roles of psychological and physiological variables as modifiable
- 0 views
- 07 Jul, 2022
- 2 locations
Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer
This stage I clinical trial compares a genetic counseling patient preference (GCPP) intervention via EHR MyChart patient portal to conventional genetic counseling for women at elevated risk for breast cancer. Women at elevated breast cancer risk may be offered genetic counseling and genetic testing to further define whether they are …
- 0 views
- 28 Jun, 2022
- 1 location
Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer
This trial studies the effect of an electronic health (eHealth) support program called PACK Health on patient reported health outcomes in patients with breast cancer. PACK Health monitors breast cancer patients' reported side effects and experience of care when receiving chemotherapy. Participating in the PACK Health coaching program may improve …
- 4 views
- 12 Jul, 2022
- 1 location